Clinical Trial Search

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) — -3.17; 4.22; 3.63; 4.34 letters

Primary: Disease-control Rate — 40; 43 percentage of subjects

Primary: Change From Baseline to Day 56 in Plasma Glucose Corrected Area Under The Plasma Concentration-Time Curve (AUC) From Time 0.5 Hours to 4.5 Hours — -13.33; -7.32; -8.72…

Primary: Change From Baseline in Brachial Artery Flow-Mediated Dilation at 6-months — -0.5; -3.4 percentage change

Primary: Change From Baseline in Hepatitis C Virus Ribonucleic Acid Viral Load at Week 12 — 6.323; 6.343; -3.935; -3.855 log10 IU/mL

Primary: Quit Rate — 18; 15 participants

Primary: Phase I: Maximum Tolerated Dose (MTD) of LBH589 When Given in Combination With Decitabine — 40 mg (level 5b dosing schedule)

Primary: Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Monotherapy — 41; 26; 44; 31 percentage of participants

Primary: Assessment of Ocular Adverse Events — 0; 0; 0 Number of Reported Adverse Events

Primary: Number of Participants Who Developed Acute Respiratory Distress Syndrome (ARDS) Within 7 Days — 20; 17 participants — p=0.53

Primary: Number of Participants With Objective Response — 5; 4; 8; 14 Participants

Primary: Change From Baseline in Area Under the Plasma Glucose Concentration Curve From Time 0.5 Hours to 4.5 Hours (GLU-AUC0:30-4:30h) at Day 28 — -227.25; -72.83 h*mg/dL…

Primary: Change From Baseline in Mean "Off" Time (Hours Per Day) at Week 12 — -1.2; -1.0; -0.9; -0.5 Hours/Day — p=0.0564

Primary: Number of Patients With Surgical Site Infections — 42; 14; 25 participants

Primary: Change From Baseline (Visit 1) of Total Corneal Fluorescein Staining Score at 12 Weeks. — -4.2; -6.2; -2.1 units on a scale